EUVIMEDEUVIMED entdecken
Crossref

Modulation of the Prostate Cancer Resistance Factor Hsp27 by the Chemotherapeutic Drugs Abiraterone, Cabazitaxel, Docetaxel and Enzalutamide

Jennifer H S Küster, Holger H H Erb, Hannes Ahrend, Alexander Abazid, Matthias B Stope

Anticancer Research · 2024

DOI: 10.21873/anticanres.17093 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Jennifer H S Küster und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Gynecological Oncology, University Hospital Bonn, Bonn, Germany. Hauptthemen laut MEDLINE: Taxoids, Docetaxel, Phenylthiohydantoin, Benzamides. Die Arbeit wurde bisher 4-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TaxoidsDocetaxelPhenylthiohydantoinBenzamidesNitrilesHSP27 Heat-Shock ProteinsDrug Resistance, NeoplasmProstatic NeoplasmsAndrostenesAntineoplastic AgentsCell ProliferationHumansMaleCell Line, TumorMolecular ChaperonesHeat-Shock Proteins

Stichwörter der Autor:innen

HSP27HSPB1PCaandrogen receptor signalingchemoresistance

Substanzen

TaxoidsDocetaxelcabazitaxelenzalutamidePhenylthiohydantoinBenzamidesNitrilesHSP27 Heat-Shock ProteinsAndrostenesAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Gynecology and Gynecological Oncology, University Hospital Bonn, Bonn, Germany.
  • Department of Urology, Faculty of Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Department of Medicine, Israelite Hospital Hamburg, Hamburg, Germany.
  • Department of General, Visceral and Thorax Surgery, Bundeswehr Hospital Berlin, Berlin, Germany.
  • Department of Gynecology and Gynecological Oncology, University Hospital Bonn, Bonn, Germany; matthias.stope@ukbonn.de.

Zitieren

APA

Küster, J. H. S., Erb, H. H. H., Ahrend, H., Abazid, A., & Stope, M. B. (2024). Modulation of the Prostate Cancer Resistance Factor Hsp27 by the Chemotherapeutic Drugs Abiraterone, Cabazitaxel, Docetaxel and Enzalutamide. Anticancer Research. https://doi.org/10.21873/anticanres.17093

Vancouver

Küster JHS, Erb HHH, Ahrend H, Abazid A, Stope MB. Modulation of the Prostate Cancer Resistance Factor Hsp27 by the Chemotherapeutic Drugs Abiraterone, Cabazitaxel, Docetaxel and Enzalutamide. Anticancer Research. 2024. doi:10.21873/anticanres.17093

BibTeX
@article{Kster2024,
  author = {Küster, Jennifer H S and Erb, Holger H H and Ahrend, Hannes and Abazid, Alexander and Stope, Matthias B},
  title = {Modulation of the Prostate Cancer Resistance Factor Hsp27 by the Chemotherapeutic Drugs Abiraterone, Cabazitaxel, Docetaxel and Enzalutamide},
  journal = {Anticancer Research},
  year = {2024},
  doi = {10.21873/anticanres.17093}
}
Kostenlos starten →